This clinical trial is focused on studying Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The study is comparing two treatments for patients who have been newly diagnosed with this condition and have undergone a procedure called autologous stem-cell transplantation, which involves using the patient’s own stem cells to help restore bone marrow. The treatments being compared are Elranatamab, also known by its code name PF-06863135, and Lenalidomide, which is available in different dosages under the brand name Zelvina.

The purpose of the study is to evaluate how effective Elranatamab is compared to Lenalidomide in treating patients with Multiple Myeloma. Participants in the study will be randomly assigned to receive either Elranatamab or Lenalidomide. Elranatamab is administered as a solution for injection under the skin, while Lenalidomide is taken orally in capsule form. The study will monitor the participants over a period of time to assess their response to the treatment and any side effects they may experience.

Throughout the study, participants will have regular check-ups and tests to track their health and the progress of their Multiple Myeloma. The main goal is to determine which treatment helps patients live longer without their disease getting worse. This information will help doctors make better treatment decisions for future patients with Multiple Myeloma.